JP2022543112A5 - - Google Patents

Info

Publication number
JP2022543112A5
JP2022543112A5 JP2022506729A JP2022506729A JP2022543112A5 JP 2022543112 A5 JP2022543112 A5 JP 2022543112A5 JP 2022506729 A JP2022506729 A JP 2022506729A JP 2022506729 A JP2022506729 A JP 2022506729A JP 2022543112 A5 JP2022543112 A5 JP 2022543112A5
Authority
JP
Japan
Prior art keywords
cells
gene
sequence encoding
group
dux4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506729A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543112A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/044635 external-priority patent/WO2021022223A1/en
Publication of JP2022543112A publication Critical patent/JP2022543112A/ja
Publication of JP2022543112A5 publication Critical patent/JP2022543112A5/ja
Pending legal-status Critical Current

Links

JP2022506729A 2019-08-01 2020-07-31 Dux4発現細胞およびそれらの使用 Pending JP2022543112A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881840P 2019-08-01 2019-08-01
US62/881,840 2019-08-01
PCT/US2020/044635 WO2021022223A1 (en) 2019-08-01 2020-07-31 Dux4 expressing cells and uses thereof

Publications (2)

Publication Number Publication Date
JP2022543112A JP2022543112A (ja) 2022-10-07
JP2022543112A5 true JP2022543112A5 (cg-RX-API-DMAC7.html) 2023-08-08

Family

ID=72088403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506729A Pending JP2022543112A (ja) 2019-08-01 2020-07-31 Dux4発現細胞およびそれらの使用

Country Status (4)

Country Link
US (1) US20220267732A1 (cg-RX-API-DMAC7.html)
EP (1) EP4007596A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022543112A (cg-RX-API-DMAC7.html)
WO (1) WO2021022223A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
US11965022B2 (en) 2020-12-31 2024-04-23 Sana Biotechnology, Inc. Methods and compositions for modulating CAR-T activity
WO2022251443A1 (en) * 2021-05-26 2022-12-01 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
WO2022269393A1 (en) * 2021-06-23 2022-12-29 Crispr Therapeutics Ag Engineered cells with improved protection from natural killer cell killing
CA3225283A1 (en) 2021-07-14 2023-01-19 Sonja SCHREPFER Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
US20260053851A1 (en) 2021-08-11 2026-02-26 Sana Biotechnology, Inc. Inducible systems for altering gene expression in hypoimmunogenic cells
AU2022325231A1 (en) * 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
US20250339531A1 (en) * 2021-11-12 2025-11-06 Fred Hutchinson Cancer Center Dux4 polypeptides and nucleic acids for treating inflammatory and autoimmune conditions
WO2023122337A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
EP4479084A1 (en) 2022-02-14 2024-12-25 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
IL318041A (en) * 2022-07-01 2025-02-01 Janssen Biotech Inc Materials and methods for bioengineered iPSC populations
WO2024012420A1 (zh) * 2022-07-11 2024-01-18 士泽生物医药(苏州)有限公司 一种表达faslg的通用型细胞及其制备方法
CN118207166A (zh) * 2022-12-16 2024-06-18 士泽生物医药(苏州)有限公司 一种通用型细胞及其制备方法
IL328729A (en) 2023-12-01 2026-07-01 Sigilon Therapeutics Inc Methods for producing stem cell-derived islet-like cells, as well as populations and compositions comprising them
WO2025230941A1 (en) 2024-04-30 2025-11-06 Satellite Biosciences, Inc. Hypoimmunogenic cell mixtures and methods of use thereof
WO2025230947A1 (en) 2024-04-30 2025-11-06 Satellite Biosciences, Inc. Engineered hepatocytes for secreting polypeptides
GB202415025D0 (en) * 2024-10-11 2024-11-27 Ospedale San Raffaele Srl Cell

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
AU2001250774B2 (en) 2000-02-08 2005-01-27 Sangamo Biosciences, Inc. Cells expressing zinc finger proteins for drug discovery
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
ATE418346T1 (de) 2004-04-08 2009-01-15 Sangamo Biosciences Inc Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
US7253273B2 (en) 2004-04-08 2007-08-07 Sangamo Biosciences, Inc. Treatment of neuropathic pain with zinc finger proteins
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
US20140115726A1 (en) 2011-04-05 2014-04-24 Cellectis New tale-protein scaffolds and uses thereof
CA2865011C (en) 2012-02-29 2021-06-15 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
US20200087629A1 (en) * 2016-10-19 2020-03-19 Fred Hutchinson Cancer Research Center Compositions and methods for reprogramming cells and for somatic cell nuclear transfer using duxc expression
KR20240095477A (ko) * 2017-01-13 2024-06-25 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 면역조작된 만능 세포
EP3601528A4 (en) 2017-03-20 2021-05-05 Washington University Cells and methods of uses and making the same
WO2020028134A1 (en) * 2018-07-30 2020-02-06 Fred Hutchinson Cancer Research Center Methods and compositions for treating cancer

Similar Documents

Publication Publication Date Title
JP2022546317A5 (cg-RX-API-DMAC7.html)
Gornalusse et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
Wu et al. Development of an inducible caspase-9 safety switch for pluripotent stem cell–based therapies
JP6516740B2 (ja) 幹細胞及びキメラ抗原受容体を介した抗腫瘍性t細胞免疫の改変
JP6346266B2 (ja) 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するt細胞受容体遺伝子の標的化された破壊
US9228007B1 (en) Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
CN115298314A (zh) 基因表达调控的安全开关
US20190161530A1 (en) Chimeric antigen receptor t cell compositions
US20230272429A1 (en) Modification of blood type antigens
Goffinet et al. Efficient nonviral gene delivery into primary lymphocytes from rats and mice
JP2022512674A (ja) 人工トランス活性化因子による選択
JP2025061188A (ja) キメラサイトカイン受容体
Su et al. Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies
KR20210116531A (ko) 영양 장애형 표피 수포증 치료약
Zhang et al. Adoptive T cell therapy following haploidentical hematopoietic stem cell transplantation
WO2022018884A1 (ja) 栄養障害型表皮水疱症の治療薬
Amrolia et al. Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation
US11903969B2 (en) Genome editing of graft-derived T-cells for post-transplant immunotherapy
CN111499766B (zh) 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用
JP7807756B2 (ja) 所望の特異性を有するエフェクター細胞の製造方法
KR102906951B1 (ko) 내인성 항원 제시 기전을 이용한 저면역원성 줄기세포 및 이의 제조 방법
Moen Transfection of Stem Cells and Gene Therapy
EA053040B1 (ru) Универсальная клетка и способ ее получения
Wang et al. 187. Comprehensive Integration Site Analysis of One New Gene Therapy Vector AAV-rDNA
WO2025181283A1 (en) Cell